Document:

Maybank
Islamic

 

 

Our Ref Date

S2H/SNS -
KJG/SR/PK/DA/HUZ/2016 - 14334
(LO)

10t
h October, 2016

 

BIO LIFE NEUTRACEUTICALS SON. BHD.

Lot 6, Jalan Ria 3 Taman
Perindustrian Ria

Batu
18, Off Jalan Semenyih 43000
Kajang

Selangor.

 

 

Dear Sir/Madam,

 

 

Re Branch

 

Islamic
Banking Facility(s) Kajang Prima

 

 

 

We
are pleased to advise you that the Bank has approved your
application under SME Property & Business Financing-i, subject to the following
terms and conditions:-

 

		1.	FACILITY(S)

 

Fund
for Small & Medium Industries 2-i (FSMl2-i)
Commodity Murabahah Term Financing-i (CMTF-i)

 

Cash Line-i (CL-i)

 

 

TOTAL

FACILITY AMOUNT

 

 

RM2,800,000-00
RM1,000,000-00

RM3,800,000.00

 

 

The limit for each
of the above facility may be varied at any
time at the Bank's discretion.

 

 

		2.	PURPOSE(S)

 

 

CMTF-i
& CL-iFor working
capital requirements.

 

Each Facility is
to be utilized for
purposes not contrary to Shariah principle
s.

 

 

		3.	BANK'S SALE PRICE

 

CMTF-i CL-i

RM6,926,058-44.

 

RM1,532,500

 

MIB/SME Property & Business
Financing-i/ LO (02092014)

Page 1
of 44

Bio
Life Neutraceuticals
Sdn.
Bhd. (870055-M)

 

Maybank
Islamic Berhad (787435-MJ

Kajang
Business Centre

1st
& 2nd Floor, Maybank Building, 28-30,
Jalan Tukang, 43000
Kajang, Selangor.

Tel:
03-87391705, 87391706,
87391707 Fax: 03-87391704MIB
01

    	 

    	 

    

 

 

 

		4.	CEILING PROFIT RATE (MURABAHAH BASED PRODUCTS ONLY)

 

The Bank's Sale Price
is based on a Ceiling Profit Rate of Base Financing Rate (BFR) + 4.00% per annum (p.a.) or 10.00% p.a. whichever is higher.

 

BFR is the rate from
time to time stipulated by the Bank as its Base Financing Rate. Currently the BFR is 6.65% p.a. and therefore, the Bank's Sale
Price is calculated at 10.65% p.a.

 

Notwithstanding the Ceiling
Profit Rate above, the payment of the Bank's Sale Price is based on the Effective Profit Rate.

 

 

		5.	PRICING (EFFECTIVE PROFIT RATE)/ COMMISSION/
CHARGES CMTF-iEffective Profit Rate:

FSMI2-i

 

1st
5 years Thereafter

 

 

BNM Rate+ 2.50% p.a. on daily rest. BFR -
1.80% p.a. on daily rest.

 

CL-iEffective Profit Rate:

 

FSMl2-i

 

1st
5 years Thereafter

 

 

BNM Rate+ 2.50% p.a. on daily rest. BFR
+ 0.50% p.a. on daily rest.

 

Bank Negara Malaysia (BNM) Rate is 1.50% p.a.

 

The Effective Profit
Rate may vary on the movement of BFR/BNM rate, provided always that it shall not exceed the Ceiling Profit Rate.

 

 

		6.	FACILITY TENURE CMTF·i

 

CL·i

 

 

 

Up to twenty (20) years
from the date the Facility is made available by the Bank.

 

Five (5) years from the
date the Facility is made available or renewed by the Bank.

 

Notwithstanding
any other provisions herein stated related to the availability of the Facility or any part thereof, the Bank reserves the right
to cancel the Facility or any part thereof at any time it deems fit or such part thereof shall be cancelled upon an event default
and the whole indebtedness or such part thereof shall be payable on demand.

 

 

 

 

 

 

 

 

 

 

 

MIB/SME Property
& Business Financing-i/ LO (02092014)

Page 2 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

		7.	PAYMENT

 

7.1
CMTF-i

 

		a.	By monthly equal installments of RM18,248.00 until full settlement
of the Facility, and

 

		b.	Profit to be serviced monthly in arrears.

 

		7.2	CL-i

 

Profit Portion

 

The profit portion
shall be realised on a monthly basis based on the Effective Profit Rate by way of:-

 

		a.	The Bank debiting your Current Account with
the Bank ("Designated Current Account") every month end and you are to ensure you pay such amount debited to avoid the
Designated Current Account being in excess;

 

		b.	Payments made directly to the Bank by you in
the manner as determined by the Bank if the available limit is already fully utilised.

 

Principal Portion (Facility Amount)

 

By bullet payment until
all amounts under the Facility are fully paid within the Facility Tenure.

 

Payable on demand.

 

 

		8.	AVAILABILITY PERIOD

 

CMTF-i

 

Subject
to fulfilment of all Conditions Precedent, the Facility shall be available for six (6) months from the acceptance date of this
Letter of Offer or such other extended period as may be determined by the Bank. Any amounts not disbursed at the end of the Availability
Period shall be cancelled thereafter.

 

CL-i

 

The
Facility shall be made available by the Bank upon fulfilment of all conditions precedent and such other terms as may be required
by the Bank but subject always to the Bank's review from time to time.

 

 

		9.	PROCESSING FEE Waived.

 

 

 

 

 

 

 

MIB/SME Property &
Business Financing-i/ LO (02092014)

Page 3 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

 

 

    	 

    	 

    

 

 

		10.	SECURITY DOCUMENTS

 

CMTF-i &
CL-i

 

		a.	Letter of Offer;

 

		b.	Pending issuance of the individual/strata
title, Deed of Assignment of the Sale and Purchase Agreement with Power of Attorney, to transfer or otherwise deal with the property
i.e. a 3 storey semi-detached factory identified as No. 9, Jalan P4/8B, Bandar Teknologi Kajang, 43500 Semenyih, Selangor, held
under H.S.(M) 5480, H.S.(M) 5481, H.S.(M) 5482, H.S.(M) 5483, H.S.(M) 5484, H.S.(M) 5485 &
H.S.(M) 5486, PT 9772, PT 9773, PT 9774, PT 9775, PT 9776, PT 9777 &
PT 9778, Mukim Semenyih, Daerah Hutu Langat, Negeri Selangor.

 

Subsequently,
upon issuance of the individual/strata title, 1st Party
Legal Charge to be created over the property.

 

CMTF-i

 

		a.	Asset Sale Agreement for RM6,926,058-44 over
Shariah compliant commodities determined by the Bank as per the e-certificate or such other evidence of ownership maintained by
the Bank for this Facility (specimen as per Attachment herein).

 

		b.	Master Facility Agreement.

 

		c.	Joint and Several Guarantee to be executed by:-

 

	
        Name

        i.     
        Chong Khoi You 

        ii.    
        Phang Lai Sim

         
	
        I/C No.

        Redacted

        Redacted

 

 

CL-i

 

		a.	Asset Sale Agreement for RM1,532,500-00 over
Shariah compliant commodities determined by the Bank as per the e-certificate or such other evidence of ownership maintained by
the Bank for this Facility (specimen as per Attachment herein).

 

		b.	Master Facility Agreement.

 

		c.	Joint and Several Guarantee to be executed by:-

 

	
        Name

        iii.   
        Chong Khoi You 

        iv.  
        Phang Lai Sim

         
	
        I/C No.

        Redacted

        Redacted

 

and such other documents or security documents
as the Bank or the Bank's solicitors may advise from time to time.

 

All obligors shall hereinafter be collectively referred to
as "Security Party".

 

 

 

 

 

 

MIB/SME Property &
Business Financing-i/ LO (02092014)

Page 4
of 44

Bio Ufe Neutraceuticals Sdn. Bhd. {87005S·M)

    	 

    	 

    

 

 

		11.	CONDITIONS PRECEDENT

 

		a.	The facilities are available for your use:-

 

		i.	Upon acceptance of this Letter of Offer (LO)
and the original copy has been returned to us.

		ii.	To forward
Board Resolution authorizing the acceptance of the Letter of Offer (only applicable for private limited entities).

		iii.	Compliance of all terms and conditions as stipulated in this
LO.

 

		b.	Winding-up and bankruptcy searches to be
conducted on your company/corporate guarantor and directors/sole-proprietor/partners/guarantors/3'' party depositors respectively,
and to reveal no adverse remarks (where applicable).

 

		c.	Prior to any disbursement of the facility,
submission of valuation report from our panel valuer indicating the property's Open Market Value of not less than RM4,500,000-00
must be obtained. Notwithstanding, the Bank shall be entitled to request for another valuation report from other panel valuers
or conduct its own internal valuation on the property's Open Market Value. ln the event the property's Open Market Value in the
valuation report by any one of the panel valuers or the bank's internal valuation of the property indicates that the Open Market
Value is less than RM4,500,000-00, the Bank shall be entitled to exercise its right to reduce the financing amount accordingly
and/or impose such other terms and conditions as it deems fit or shall be entitled to exercise its rights to declare an event of
default and exercise its rights hereof, as the case may be.

 

		d.	A Variable Standing Instruction (VSI) to
be executed by you for the payment of CMTF-i via Islamic Current Account.

 

		e.	An Islamic Current Account is to be opened
by you, within 7 working days from the date of acceptance
of this LO (if not done so).

 

		f.	Mortgage Reducing Term Takaful (MRTT)/Mortgage
Reducing Term Assurance (MRTA) to be taken by the key sponsor(s) of your company/business from the Bank's approved takaful operator
/insurance company.

 

		g.	Fire takaful/insurance / Contractors All
Risk / Fire takaful/insurance under Buildings In the Course of Construction (BICC) to be taken on the proffered property from the
Bank's approved takaful operator /insurance company.

 

		h.	Submission of Audited Financial Statement
for Financial Year Ended (FYE) 31/12/2015 with negative variance of not more than 10% for Turnover, Profit Before Tax, and Total
Networth as compared to the Management Account submitted for the same financial period.

 

		i.	Submission of documentary evidence showing
that the purchase price of the proffered property has been fully paid by you.

 

		j.	Satisfactory completion of all legal documentation as advised by
the solicitors of the Bank.

 

		k.	Conditions precedent as indicated in the General Terms and Conditions
in Annexure 2.

 

		12.	OTHER TERMS AND CONDITIONS

 

		a.	Pending availability of FSMl2-i funding from
BNM, the facilities are to be priced at the thereafter rate of BFR - 1.80% p.a. (for CMTF-i) and BFR +
0.50% p.a. (for CL-i).

 

 

 

 

MIBISME Property & Business Financing-i/
LO (02092014)

 

Page 5 of 44

Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

 

    	 

    	 

    

 

 

		13.	BENEFITS

 

		a.	Maybank2u.com Biz product shall be offered
to you (if you are not our existing user yet) for convenience of using online banking.

 

		b.	Mortgage Reducing Term Takaful (MRTT)/Mortgage Reducing Term Assurance
(MRTA)

 

MRTT/MRTA
shall be offered to you (key person/managing director/director(s)/managing partner/partner(s)/proprietor) for takaful/insurance
coverage on the property financed/charged. MRTT/MRTA shall be taken from the Bank's approved takaful operator /insurance company.

 

		c.	Takaful Overdraft Protector Plus (Takaful ODP Plus)/Overdraft Protector
Plus (ODP Plus)

 

You
shall take (Takaful ODP Plus/ODP Plus) on your own cost from the Bank's approved takaful operator/insurance company.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MIB/SME Property
& Business Financing-i/ LO (02092014)

Page 6 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

The
Facility is also subject to the
terms and conditions as set out
in Annexure 1
and Annexure 2
to this letter together with such other appendixes (if any), attachments
and the Security Documents, which
shall form an integral
part of this Letter of Offer.

 

This
Letter of Offer shall
be valid for a
period of seven (7) working days
from the date hereof
or such other extended period as may be determined
by the Bank. In the event
that it is not duly
accepted, signed and
returned to us within
the aforesaid period, the offer herein contained shall
unless so extended
by the Bank lapse and be
of no further effect.

 

We
thank you for giving
us the opportunity to
be of service to you
and we look forward to
your acceptance of the offer.

 

 

Thank
you.

 

 

Yours faithfully,

For
MAYBANK ISLAMIC BERHAD

 

 

 

/s/THIM
LEE CHU

 

 

 

EDWIN
LIM SWEE
AUN

PF:
88916

H/P:
01 2-793 6S45

/s/ LIM SWEE AUN

THIM LEE CHU

SME Manager
Zone Kajang

LIM SWEE AUN

Business
Development Executive Zone Kajang

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MIB /SME
Property &
Business Financing-i/ LO /02092014)

Page
7 of 44 Bio
Life Neutraceuticals
Sdn.
Bhd.
(870055-M)

    	 

    	 

    

 

 

 

ACKNOWLEDGEMENT

 

		a.	Subject to the
terms and conditions of the legal documentation
to be executed, I/
we further agree that
this letter embodies
in writing all and
the entire terms of
our agreement and I/we hereby
declare and confirm
that no warranties,
promises,
representations,
collateral agreements have been made to me/us and if,
which is denied,
that
any such warranties, promises, representations
or collateral agreements were made
they have now lapsed
and are superseded by this
letter and be of no effect whatsoever.

 

		b.	I /
We acknowledge that I/we have read
and understood the contents of this
Letter
of Offer and I /
we further
warrant that I/we have
been advised to sought independent legal
advice and acknowledge the obligations arising there
from.

 

		c.	If I/we
are external account holder(s) or a non-resident controlled company, my/our
total borrowings/financing in Malaysia does/do not exceed the amount
as specified by the Controller of Foreign Exchange) and
undertake to inform you immediately should
my/our borrowings/financing exceeds the amount as specified by the Controller of Foreign
Exchange.

 

		d.	I/We further
agree and authorise the Bank
to make the relevant
credit
references with any external
parties including but not
limited to CCRIS,
FIS, CTOS and any other credit reference
agencies and that in so
doing the Bank shall be entitled to disclose such information as
may be necessary
in order for the
external parties to provide
the Bank with
the references/confirmation
sought.

 

 

 

 

 

Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

(Formerly
known as CK Harvest (M) Sdn. Bhd.) Lot 6, Jalan Ria 3, Kawasan Perindustrian Ria, Jalan Semenyih, 43000 Kajang, Selangor.

Tel/Fax:
03-8740 6720

 

/s/CHONG KHOOI YOU

Authorized
Signatories and Company Chop

for
BIO LIFE NEUTRACEUTICALS SDN. BHD. (870055 -M)

Name:
NRIC:

(       Date:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MIB/
SME Property
& Busin
ess
Financing-
-i/
LO (02092014)

 

Page
8 of 44
Bio Life Neutraceuticals
Sdn. Bhd. (870055-M)

 

 

    	 

    	 

    

 

 

ANNEXURE 1

 

SPECIFIC TERMS AND
CONDITIONS

PART A

 

CASH LINE-i

 

		1.	Method of Financing

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		2.	Purchase Request and Undertaking

 

 

In
accordance with the contract of Murabahah
(Cost Plus Sale) and the Bank's financing procedures, upon the acceptance of the Letter of Offer for the Facility, you
will request the Bank to purchase the underlying Shariah compliant commodities acceptable to the Bank (Commodity) from such commodity
trader acceptable to the Bank and undertake to purchase the Commodity from the Bank. Pursuant to the request, the Bank will purchase
the Commodity from any commodity trader at the price equivalent to the Facility Amount.

 

Thereafter,
the Bank shall sell to you the Commodity and you shall purchase the Commodity at the Bank's Sale Price which shall constitute the
Facility Amount and the Bank's Profit on deferred payment basis.

 

You
shall also appoint the Bank as your agent to sell the Commodity to any commodity trader or any third party at an amount which shall
be equivalent to the Facility Amount.

 

The
proceeds of the sale of the Commodity shall be emplaced in the Designated Current account for disbursement subject to the terms
of the Facility and as may be determined by the Bank from time to time.

 

In
accordance with the financing procedures of the Bank, you hereby request the Bank to purchase the Commodity from any commodity
trader at the Facility Amount which shall be payable in accordance to the terms of the Facility.

 

You
hereby promise and irrevocably undertake to purchase the Commodity from the Bank, at the Bank's Sale Price.

 

You
confirm that the undertaking herein is irrevocable (except with the prior written consent of the Bank) and binding on your estate,
heirs, successors in title, permitted assigns and personal representatives.

 

 

 

 

 

 

 

 

 

 

MIB/SME Property &
Business Financing·i/ LO (02092014)

Page 9 of
44

Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

 

 

 

 

 

 

 

 

 

 

		3.	Appointment of Agency

 

You
undertake to fully indemnify and keep the Bank indemnified from or against any expenses, loss, damages or liabilities resulting
from any defect, malfunction and/or the lack of merchantable quality of the Commodity or lack of fitness for use of the Commodity
or otherwise howsoever in connection with this Purchase Request and Undertaking including against any loss in any manner whatsoever
which the Bank may suffer as a result of the Bank agreeing to participate in the commodity Murabahah
transaction.

 

You
hereby irrevocably appoint the Bank as your agent to the effect that the Bank may perform the following:-

 

		i.	to purchase the commodity that the Bank deems
fit and to take possession (physical or constructive) of the Commodity;

 

		ii.	sell the Commodity to any commodity trader
or any third party at the price equivalent to the Facility Amount;

 

		iii.	receive proceeds from the sale of the Commodity
on your behalf; and

 

		iv.	to deliver possession of and title in and
to the Commodity to any purchaser of the Commodity.

 

The
Bank shall at all times act as your undisclosed agent and the Bank shall:-

		a.	be authorised to sign and execute all documents
and do all acts and observe and perform all obligations required to be done in connection with the appointment as agent, or imposed
under any agreement of sale of the Commodity to any commodity trader or third party; and

		b.	be authorised to delegate its rights and
duties as an agent herein to any third party to do all acts necessary for the completion of the required transactions; and

		c.	be required to do all the administrative
duties regarding the holding and the selling of the Commodity thereof.

 

Bank as your agent to execute documents

In
addition to the appointment of agency as stated above, you hereby appoint the Bank as your agent to perform the following for and
on your behalf:·

		a.	to act and/or execute the necessary documents
under the commodity Murabahah transaction

(including but not
limited to the Asset Sale Agreement); and

 

 

MIB/SME Property
& Business Financing-i/ LO (02092014)

Page 10 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

    	 

    	 

    

 

 

 

		b.	to act and/or execute the necessary documents
under the commodity Murabahah transaction (including
but not limited to the Asset Sale Agreement) for the renewal of the Facility;

 

Save
for the purpose of this appointment, the appointment shall not create or be deemed to create a partnership or a joint venture between
the parties, nor shall it establish a relationship of principal or agent in any other relationship between the Bank and you.

 

 

 

 

 

 

 

		4.	Disbursementofthe
Facility Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		5.	Renewal of Facility

You
hereby agree that you shall indemnify and keep the Bank indemnified from any losses, costs, expenses or damage that the Bank may
suffered or incur as a result of fulfilling the Bank's agency function as set above.

 

		a.	The Facility shall be made available by
the Bank for utilisation into the Designated Current Account.

 

		b.	The utilisation of such amount from the
Designated Current Account shall be effected from time to time by cheques drawn on the Bank by you or by such other modes as acceptable
to the Bank.

 

		c.	The availability of the
Facility in the Designated Current Account in the above stated manner by the Bank shall be deemed to be effective payment thereof
to or for your benefit.

 

		d.	The utilisation of the Facility is subject
always to the fulfilment of all conditions as set out by the Bank including but not limited to the perfection of all Security Documents.

 

		a.	The Facility is granted conditional upon
you conducting your account with the Bank satisfactorily at all times.

 

		b.	The Bank may at its absolute discretion grant
a renewal of the Facility subject to the new Facility Tenure and upon such terms and conditions as may be deemed fit by the Bank.

 

		C.	If the Bank agrees to grant renewal of the Facility, the Bank may issue
notice of renewal to you prior to the expiry of the existing Facility Tenure. If the Bank does not receive any reply from you to
decline the renewal, it is deemed that you are agreeable to such renewal.

 

 

 

 

MIB/SME Property & Business Financing-i/ LO (02092014)

 

Page 11 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

    	 

    	 

    

 

 

		d.	On such renewal, all proceeds of the new
or renewed Facility shall first be applied towards the payment of all amounts then outstanding and due to the Bank under the Facility
without further notice or demand.

 

 

 

 

 

 

		6.	Terms and conditions of Sale of Commodity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		7.	Takaful ODP Plus / ODP Plus
(If applicable)

		e.	Any renewal, once approved by the Bank,
shall be affected by way of you or your agent and the Bank executing the relevant documentation as required by the Bank.

 

The
sale of the Commodity by the Bank shall be governed by the terms and conditions of the Letter of Offer.

 

The
Customer shall obtain such title to the Commodity as the Bank receives from the commodity trader free from encumbrances. The Bank
shall not be deemed to give any warranty or representation (express or implied) whatsoever, whether arising by law, by statute
or otherwise and, without prejudice to the generality of the foregoing, any such warranty or representation by the Bank is hereby
expressly excluded to the full extent permitted by any applicable law.

 

The parties
hereby agree that upon the sale of the Commodity by the Bank to the Customer, the Customer shall bear full ownership and responsibilities
towards the Commodity.

 

The
Customer agrees that in purchasing the Commodity from the Bank, it shall have accepted the Commodity on
an 1as is, where is' basis.

 

The
Customer hereby waives any claims which it may have against the Bank in respect of any loss or damage which he may suffer by reason
of, or arising out of or in connection with the Letter of Offer or any other security documents or otherwise (howsoever arising)
in connection with or arising from the purchase of the Commodity.

 

		a.	Takaful Overdraft Protector Plus (Takaful
ODP Plus)/Overdraft Protector Plus (ODP Plus) (overdraft coverage) shall be taken-up from the Bank's approved takaful operator
/insurance company.

 

		b.	The Takaful ODP Plus/ODP
Plus coverage is to be taken prior to the release of the Cash Line-i facility. Unless provided otherwise, the Takaful ODP Plus
contribution is to be paid from the facility amount. In the event the Takaful ODP Plus contribution is not to be paid from the
facility amount, you shall finance the contribution charged. In the event you opt for ODP Plus, you shall finance the premium charged.
The renewal

Page 12 of 44

MIB/SME Property
& Business Financing-i/ LO (02092014)

Bio life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

contribution/ premium,
if any, shall be advised accordingly in the yearly renewal notice.

 

		c.	In the event the Takaful ODP Plus/ODP Plus
is deemed substandard, the Bank's approved takaful operator /insurance company may charge additional contribution/ premium or health
loading contribution/premium. Under such circumstances, you shall finance the additional contribution/premium charged.

 

		d.	In the event of the inability on your part
to satisfy the requirements imposed by the Bank's approved takaful operator/insurance company for the Takaful ODP Plus/ODP Plus
coverage resulting in no Takaful ODP Plus/ODP Plus coverage in respect of the Cash Line·i offered by the Bank's approved
takaful operator/insurance company vide this letter of offer, you confirm that you fully understand the consequential effects that
such absence of the Takaful ODP Plus/ODP Plus and therefore agree not to hold the Bank responsible.

 

		e.	In the event that you have requested the
Bank for waiver of Takaful ODP Plus/ODP Plus coverage or in the event of the inability on your part to satisfy the requirements
imposed by the Bank's approved takaful operator /insurance company for the Takaful ODP Plus/ODP Plus coverage resulting in the
Takaful ODP Plus/ODP Plus coverage in respect of the Cash Line·i facility offered by the Bank's approved takaful operator/insurance
company vide this letter of offer is not for the full facility amount and/or not for the full tenure of the facility(s), you confirm
that you fully understand the consequential effects that such absence of the Takaful ODP Plus/ODP Plus and therefore agree not
to hold the Bank responsible.

 

 

PART B

 

COMMODITY MURABAHAH TERM FINANCING·i
(CMTF•i)

 

		1.	Method Financing

of
In accordance with the contract of Murabahah (Cost Plus Sale) and
the Bank's financing procedures, upon the acceptance of the Letter of Offer for the Facility, you will request the Bank to purchase
the underlying Shariah compliant commodities

acceptable to the
Bank (Commodity) from such commodity trader acceptable to the Bank and undertake to purchase the Commodity from the Bank. Pursuant
to the request, the Bank will purchase the Commodity from any commodity trader at the price equivalent to the Facility Amount.

 

Thereafter,
the Bank shall sell to you the Commodity and you shall purchase the Commodity at the Bank's Sale Price which shall constitute the
Facility Amount and the Bank's Profit on deferred payment basis.

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 13 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

 

    	 

    	 

    

 

 

 

You
shall also appoint the Bank as your agent to sell the Commodity to any commodity trader or any third party at an amount which shall
be equivalent to the Facility Amount.

 

 

 

 

 

 

 

		2.	Purchase Request and
Undertaking

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		3.	Appointment of Agency

The
proceeds of the sale of the Commodity shall be emplaced in your designated current account maintained with the Bank ("the
Designated Current Account") for disbursement subject to the terms of the Facility and as may be determined by the Bank from
time to time.

 

In
accordance with the financing procedures of the Bank, you hereby requests the Bank to purchase the Commodity from any commodity
trader at the Facility Amount which shall be payable in accordance to the terms of the Facility.

 

You
hereby promise and irrevocably undertake to purchase the Commodity from the Bank, at the Bank's Sale Price.

 

You
confirm that the undertaking herein is irrevocable (except with the prior written consent of the Bank) and binding on your estate,
heirs, successors in title, permitted assigns and personal representatives.

 

You
undertake to fully indemnify and keep the Bank indemnified from or against any expenses, loss, damages or liabilities resulting
from any defect, malfunction and/or the lack of merchantable quality of the Commodity or lack of fitness for use of the Commodity
or otherwise howsoever in connection with this Purchase Request and Undertaking including against any loss in any manner whatsoever
which the Bank may suffer as a result of the Bank agreeing to participate in the commodity Murabahah
transaction.

 

You
hereby irrevocably appoint the Bank as your agent to the effect that the Bank may perform the following:-

 

		i.	to purchase the commodity that the Bank deems
fit and to take possession (physical or constructive) of the Commodity;

 

		ii.	sell the Commodity to any commodity trader
or any third partyat the price equivalent to the Facility Amount;

 

		iii.	receive proceeds from the sale of the Commodity
on your behalf; and

 

		iv.	to deliver possession of and title in and
to the Commodity to any purchaser of the Commodity.

 

Bank as your agent to execute documents

In
addition to the appointment of agency as stated above, you hereby appoint the Bank as your agent to perform the following for and
on your behalf:

		a.	to act and/or execute the necessary documents
under the commodity Murabahah transaction (including
but not limited to the Asset Sale Agreement); and

 

 

M/B/SME Property
& Business Financing-i/ LO (02092014)

Page
14 of 44 Bio life Neutraceuticals
Sdn. Bhd. {870055-M)

 

    	 

    	 

    

		•	.r;..

 

 

 

 

 

 

 

 

 

		b.	to act and/or execute the necessary documents
under the commodity Murabahah transaction (including but not limited to the Asset Sale Agreement) for the renewal of the
Facility, if applicable;

 

Save
for the purpose of this appointment, the appointment shall not create or be deemed to create a partnership or a joint venture between
the parties, nor shall it establish a relationship of principal or agent in any other relationship between the Bank and you.

 

 

 

 

 

 

		4.	Terms and conditions
of

Sale of

Commodity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		5.	MRTT/MRTA (If applicable)

You
hereby agree that you shall indemnify and keep the Bank indemnified from any losses, costs, expenses or damage that the Bank may
suffered or incur as a result of fulfilling the Bank's agency function as set above.

 

The
sale of the Commodity by the Bank shall be governed by the terms and conditions of the Letter of Offer.

 

The
Customer shall obtain such title to the Commodity as the Bank receives from the commodity trader free from encumbrances. The Bank
shall not be deemed to give any warranty or representation (express or implied) whatsoever, whether arising by law, by statute
or otherwise and, without prejudice to the generality of the foregoing, any such warranty or representation by the Bank is hereby
expressly excluded to the full extent permitted by any applicable law.

 

The
parties hereby agree that upon the sale of the Commodity by the Bank to the Customer, the Customer shall bear full ownership and
responsibilities towards the Commodity.

 

The
Customer agrees that in purchasing the Commodity from the Bank, it shall have accepted the Commodity on an 'as is, where is'
basis.

 

The
Customer hereby waives any claims which it may have against the Bank in respect of any toss or damage which he may suffer by reason
of, or arising out of or in connection with the Letter of Offer or any other security documents or otherwise (howsoever arising)
in connection with or arising from the purchase of the Commodity.

 

		a.	Mortgage Reducing Term Takafut ("MRTT")/Mortgage
Reducing Term Assurance (MRTA) shall be taken-up from the Bank's approved takaful operator/insurance company.

 

		b.	The MRTT/MRTA coverage is to be taken prior
to the release of the facility. Unless provided otherwise, the MRTT single contribution is to be incorporated into the facility
amount. In the event the MRTT single contribution is not to be incorporated into the facility amount, you shalt finance the contribution
charged. In the event you opt for MRTA, you shall finance the premium charged.

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 15 of 44 Bio
life Neutraceuticals Sdn. Bhd. (870055-M)

 

	
        \

 

    	 

    	 

    

 

 

		c.	In the event the MRTT /MRTA is deemed substandard,
the Bank's approved takaful operator/insurance company may charge additional contribution/premium or health loading contribution/premium.
Under such circumstances, you shall finance the additional contribution/premium charged.

 

		d.	In the event of the inability on your part
to satisfy the requirements imposed by the Bank's approved takaful operator/insurance company for the MRTT/MRTA coverage resulting
in no MRTT / MRTA coverage in respect of the facility(s) offered by the Bank's approved takaful operator/insurance company vide
this letter of offer, you confirm that you fully understand the consequential effects that such absence of the MRTT / MRTA and
therefore agree not to hold the Bank responsible.

 

		e.	In the event that you have requested the
Bank for waiver of MRTT / MRTA coverage or in the event of the inability on your part to satisfy the requirements imposed by the
Bank's approved takaful operator/insurance company for the MRTT/MRTA coverage resulting in the MRTT/MRTA coverage in respect of
the facility(s) offered by the Bank's approved takaful operator/insurance company vide this letter of offer is not for the full
facility amount and/or not for the full tenure of the facility(s), you confirm that you fully understand the consequential effects
that such absence of the MRTT / MRTA and therefore agree not to hold the Bank responsible.

 

 

6,PRTT /PRTA
(If

applicable)

 

		a.	Personal Reducing Term Takaful ("PRTT")/Personal
Reducing Term Assurance (PRTA) shall be taken-up from the Bank's approved takaful operator /insurance company,

 

		b.	The PRTT /PRTA coverage is to be taken prior
to the release of the facility(s). Unless provided otherwise, the PRTT contribution is to be paid from the facility amount. In
the event the PRTT single contribution is not to be paid from the facility amount, you shall finance the contribution charged.
In the event you opt for PRTA, you shall finance the premium charged.

 

		c.	In the event the PRTT/PRTA is deemed substandard,
the Bank's approved takaful operator/insurance company may charge additional contribution/premium or health loading contribution/premium.
Under such circumstances, you shall finance the additional contribution/premium charged.

 

		d.	In the event of the inability on your part
to satisfy the requirements imposed by the Bank's approved takaful operator /insurance company for the PRTT /PRTA coverage resulting
in no PRTT/PRTA coverage in respect of the facility(s) offered by the Bank's approved takaful operator/insurance company vide this
letter of offer, you confirm that you fully understand the consequential effects that such absence of the PRTT /PRTA and therefore
agree not to hold the Bank responsible.

 

 

 

MIB/SME Property &
Business Financing·i/ LO (02092014)

 

Page 16 of 44

Bio Life
Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

		e.	In the event that you have requested the
Bank for waiver of PRTT /PRTA coverage or in the event of the inability on your part to satisfy the requirements imposed by the
Bank's approved takaful operator/insurance company for the PRTT /PRTA coverage resulting in the PRTT /PRTA coverage in respect
of the facility(s) offered by the Bank's approved takaful operator/insurance company vide this letter of offer is not for the full
facility amount and/or not for the full tenure of the facility(s), you confirm that you fully understand the consequential effects
that such absence of the PRTT/PRTA and therefore agree not to hold the Bank responsible.

 

PARTC

 

FSMl2-i

 

		1.	SPECIFIC CONDITIONS FOR FSMl2-i

 

		a.	The funding under FSMl2-i scheme is subject
to Bank Negara Malaysia's (BNM) approval and availability of the Scheme funds.

 

		b.	In the event that the Scheme funds are
not approved or not available, the Bank reserves the right to revise the terms and conditions including the financing rate to the
rates set out below and notwithstanding any provisions to the contrary herein contained, the Bank's reserves the rights to terminate
the said facility by giving you notice of at least twenty one (21) days prior to the effective date of the implementation:-

 

CMTF-i CL-i

Base Financing Rate - 1.80% per annum (p.a.)

 

Base Financing
Rate + 0.50% per annum (p.a.) (payable on demand)

 

		c.	Where applicable, early
release of the facilities pending drawdown of the FSMl2-i funds is allowed subject to the Bank's approval with the profit rate
to be charged on the facility(s) as mentioned above.

 

		d.	The financing rate under the FSMl2-i scheme
(i.e. FSMl2-i Funding Rate) is for a period of five (5) years from the date of first drawdown subject to changes at BNM's discretion
and the Bank's periodic review. In the event of any change in the FSMI2·i Funding Rate, the financing rate shall be revised
accordingly.

 

		e.	The first drawdown of the financing (either
partially or wholly) from BNM to you must be made within six (6) months from the date of the confirmation of approval from BNM
("BNM Approval Date"), failing which the financing approval under the FSMI2·i scheme shall be withdrawn as per
the provisions of BNM Guidelines (including any revision thereof) in respect of FSMl2-i ("BNM FSMl2-i Guidelines").

 

 

 

 

 

 

 

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 17 of 44 Bio Life
Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

		f.	BNM reserves the right to terminate the
financing under the FSMl2-i scheme in the event:-

 

		i.	Full drawdown is not made within twelve (12) months of the BNM Approval

Date; or

 

		ii.	Any application for extension to the deadline
for disbursement is rejected by BNM; or

 

		iii.	Non-compliance with any provision of the BNM FSMl2-i Guidelines.

 

[End of Annexure 1]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MIB/SME Property &
Business Financing-i/ LO (02092014)

Page 18 of 44

Bio life Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

ANNEXURE 2

 

GENERAL TERMS
AND CONDITIONS (where applicable)

 

 

		1.	Conditions Precedent

 

The obligation of the Bank
to make any disbursement is subject to the fulfilment in the manner satisfactory to the Bank prior to the making of any disbursement,
of the following Conditions Precedent (including but not limited to):-

 

		1.1	Conditions Precedent

 

		(a)	the Security Documents shall have been duly
executed, stamped and presented for registration with such registries as the Bank may deem necessary or expedient.

 

		(b)	searches have been conducted by the solicitors
on you and/or Security Party or your directors and/or directors of the Security Party at the Companies Commission of Malaysia ("CCM")
and Jabatan lnsolvensi Malaysia ("JIM") (whichever applicable) confirming that you and/or Security Party have
not been wound up or adjudicated bankrupt (whichever applicable).

 

		(c)	that as from the date
when you first applied for the Facility, there has been no material alterations or changes or event or events occurred which could
or might materially or adversely affect your and/or Security Party's financial condition or otherwise or your and/or Security Party's
ability to observe and perform their obligations under this letter and other Security Documents which could or might adversely
affect decision of the Bank to proceed with the granting of the Facility.

 

		(d)	you and/or Security Party (where applicable)
has disclosed to the Bank all material facts known to you/them relating to your/their financial conditions.

 

		(e)	you and/or Security Party are not in default
under any agreement to which you/they are party or by which you/they may be bound and no litigation arbitration or administrative
proceedings are presently current or pending or threatened which default litigation arbitration or administrative proceedings as
the case maybe might in the opinion of the Bank (which opinion shall not be questioned on any account whatsoever) materially affect
your and/or Security Party's solvency or might affect your and/or Security Party's ability to observe and perform your/their obligations
under this letter and other Security Documents.

 

		(f)	the Bank is satisfied that no event has
occurred so as to render any indebtedness under the Facility to become immediately payable and no Event of Default under the Facility
has occurred or is threatened.

 

 

 

 

 

MIB/SME Property & Business Financing
–i/ LO (02092014)

 

Page 19 of 44
Bio Ufe Neutraceuticals Sdn. Bhd. (870055-M}

    	 

    	 

    

 

 

		(g)	the solicitors shall have certified that
a search on the property at the relevant land registry or office showed that the property is free from any encumbrances whatsoever
and, where applicable, there are no restrictions in interest affecting the property. In the event there is any restriction in interest,
prior written consent should have been obtained from the relevant authority.

 

		(h)	For property held on land that is in the
process of status conversion to "industrial or commercial", disbursement of
funds is subjected upon payment of premiums for the conversion of land. Otherwise the Bank reserves
the rights to revise, vary, reduce or cancel the facility(s) offered as it deemed fit.

 

		(i)	Letter of Undertaking from master chargee
or any other chargee bank (if any) to exclude the property
in the event of any foreclosure proceedings taken against the property and disclaiming all rights and interests over the property
have been obtained.

 

		(j)	Letter of Undertaking from vendor / developer
to forward a copy of the individual title/strata title to the property upon issuance free from encumbrances and to further undertake
to refund all monies released in the event that the transfer cannot be registered for whatsoever reasons.

 

		(k)	there shall have been obtained all approvals,
consents, authorizations and licenses, including but not limited to those which are corporate or which may be required from any
governmental or statutory or regulatory authorities or creditors, which are necessary or expedient for the obtaining of the Facility
from the Bank hereunder, the execution where appropriate, registration of the Security Documents in respect of the Facility, the
carrying out of your business and/or affairs and for the transactions herein contemplated.

 

		(l)	you and/or any other relevant party shall
have fulfilled, in a manner satisfactory to the Bank, all other conditions precedent as set out in the Letter of Offer or any further
conditions as advised by solicitors of the Bank or conditions which may subsequently be imposed by the Bank.

 

		2.	Execution of Security Documents

 

 

 

 

 

		3.	Trading Fee

Notwithstanding anything
to the contrary, the Facility is conditional upon the preparation, execution and perfection of the Security Documents as stated
herein. If you do not fulfill such conditions within 30 days from the date of acceptance of this letter (or such other extended
time as may be permitted by us from time to time), the Bank reserves the right to vary or terminate the Facility at the Bank's
sole discretion.

 

A
trading fee of RM15 per every RM1.0 million of the Facility Amount to be paid to the Bank with respect to the commodity Murabahah
transaction unless waived ar varied by the Bank.

 

 

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

 

Page
20 of 44 Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

 

 

		4.	Termination and Acceleration

 

 

 

 

 

 

 

 

 

 

 

		5.	Credit Bureau

 

 

 

 

 

 

 

 

		6.	Cost and
Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

		7.	LatePayment
Charges (LPC)

 

Notwithstanding
any other prov1S10ns herein stated relating to the payment and availability of the Facility, the Bank reserves the right in the
event of default, to terminate and accelerate payment of the Bank's Sale Price at any time it deems fit by giving written notice
of the same, whereupon the Facility or such part thereof shall be terminated and the whole indebtedness or such part thereof shall
be payable upon demand.

 

Without
prejudice to the generality of the foregoing, the Bank reserves the right to terminate and accelerate payment of the Bank's Sale
Price if the facility(s) is utilised for any purpose which is in contravention of the Shariah principles as determined by the Bank.

 

Bank
Negara Malaysia (BNM) has established the Credit Bureau, to collect information from banks regarding the credit facilities, which
they grant to their customers. This is to enable participating banks that are approached for credit facilities by a customer to
be informed by the Credit Bureau of the aggregate credit facilities granted to the customer by other banks. This information to
be kept strictly confidential between the Credit Bureau and all other participating banks and it is a term of this Facility that
information regarding it will be given to the Credit Bureau for the use of the Credit Bureau and the participating banks.

 

All
costs, expenses including legal fees (on a solicitor and client basis), stamp duty, incidental fees or other charges incurred in
the preparation of all documentation and perfection of the Bank's security shall be borne by you. In the event that the Facility
is cancelled by you, the Bank reserves the right to recover from you all legal fees, stamp duty, disbursements valuation fees and
cost incurred or suffered by the Bank arising from or relating to this Facility (including those which the Bank had agreed to bear
as aforesaid) by any method the Bank deems necessary without further notice, including, the right to debit any account maintained
by you with the Bank. You shall be liable to pay all fees and expenses including the Bank's legal fee, for any monies that shall
be required to be recovered by any process of law or by the Bank's solicitors or such other parties appointed by the Bank.

 

		a.	It is expressly agreed by the parties that
the Bank shall have the right to be compensated on late instalment and/or default payment based on the following mechanism:-

 

		(i)	Overdue installment or Scheduled Payment

For
failure to pay any instalment or any payment due from the date of the first disbursement of the Facility until its expiry or maturity
date, an LPC sum equivalent to one per cent (1.00%) per annum of the overdue instalments/payment or by any other method approved
by Bank Negara Malaysia (BNM);

 

 

 

 

 

MIBISME Property & Business Financing-i/
LO (02092014)

Page 21 of 44

Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

 

		(ii)	Upon Maturity

For
failure to pay any instalments or any payment due and which failure continues beyond the expiry or maturity date of the Facility
or upon judgment, whichever is earlier, at the LPC rate which shall be the prevailing daily overnight Islamic Interbank Money Market
(IIMM) rate on the outstanding balance due and payable or any other method approved by Bank Negara Malaysia from time to time.

 

		b.	Notwithstanding the amount of LPC charged,
it is expressly acknowledged and agreed that the said amount of LPC shall not be further compounded.

 

 

 

 

		8.	Rebate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		9.	Default/ Funding Rate

The
LPC shall be applied to the judgment sum and shall be payable from the date of the judgment is made until the date of actual payment.

The
Bank shall grant rebate (/bra') to you for any sale based Facility on, but not limited to, the following events:·

 

		a.	Early settlement or early redemption, including
those arising from prepayments;

		b.	In the event of early commencement of Monthly
Instalment prior to the expiry of grace profit period (for properties under construction); and

		c.	In the event the Effective Profit Rate is
lower than the Ceiling Profit Rate.

		d.	In the event the actual disbursed amount
is less than the Facility Amount.

 

For
avoidance of doubt, it is hereby acknowledged and agreed that the rebates referred to herein shall not be construed in. any manner
whatsoever as cash rebate payable to you, but shall be reflected as a reduction in the profit element of the Bank's Sale Price.
The rebate shall only be deemed granted upon receipt of the settlement/redemption sum as determined by the Bank based on the following
formula:-

 

	
        Outstanding Bank's

        Sale Price
	
         

        LESS
	Outstanding Facility Amount	
         

        LESS
	Other Amount Due to the Bank

 

		(a)	Default Clause

In
the event of you default on three (3) consecutive months in any due payment or your Cash Line-i account is in excess of the limit
for three (3) consecutive months under the Facility, the Bank shall be entitled to increase the profit margin of the Effective
Profit Rate to BFR + 2.5% p.a. or 1.0% p.a. above the Effective Profit Rate
(if the Effective Profit Rate is BFR + 2.5% p.a. and above) ("the Default
Rate") to be charged on the amount outstanding, or such other profit rates as the Bank may at its sole and absolute discretion
prescribe from time to time.

 

 

 

Page
22 of 44

MIB/SME
Property & Business Financing·i/ LO (02092014)Bio
Life Neutraceuticals
Sdn. Bhd. (8700SS·MJ

    	 

    	 

    

 

 

For
Term Financing where the payment for the Facility is by quarterly, half-yearly, yearly or bullet payment, the Bank shall be entitled
to increase the profit margin of the Effective Profit Rate to Default Rate to be charged on the amount outstanding, or such other
profit rates as the Bank may at its sole and absolute discretion prescribe from time to time, if the payment is due and unpaid
for three (3) months from the first day of default.

Provided
always that such increase shall not cause the total payment amount to exceed the Bank's Sale Price.

 

		(b)	Funding Clause

 

 

 

 

 

 

 

 

 

 

 

		10.	Consents,

Undertaking and Caveat

 

 

		11.	Rights of Bank

to Indebtedness

 

 

 

 

		12.	Exchange

Control

 

		13.	Review

During
the entire Facility Tenure, the Bank reserves the right to increase the prevailing Effective Profit Rate to at least BFR +
0.00% in the event the difference between BFR and Bank Negara Malaysia (BNM) Overnight Policy Rate (OPR) declines to below
2% or at least up to COF + 1% in the event the Effective Profit Rate is
lower than the prevailing COF (whichever applicable) or imposed such other reference rate as deemed appropriate by the Bank. Provided
always that such increase shall not cause the total payment amount to exceed the Bank's Sale Price.

 

You
shall by signing and accepting this letter of offer, consent and authorize the Bank to lodge any caveat or to obtain all undertakings,
disclaimers and consents to the satisfaction of the Bank which are necessary in the Bank's view for release of the Facility.

 

All
indebtedness which may include the Bank's Sale Price and/or other moneys due and payable under the Facility shall continue to be
due and payable, notwithstanding any termination of the relationship of banker and customer or any judgment or order obtained by
us until full payment is received by the Bank.

 

You
are responsible for obtaining any exchange control approvals which may be required.

 

Notwithstanding
and without prejudice to anything herein stated, the Bank may review the Facility from time to time at any time as the Bank may
in its sole discretion deem fit including any time before the utilization of the Facility.

 

The
Bank shall allow utilization or disbursement of the Facility or any portion thereof subject only to the Bank being satisfied that
the review exercise indicate, there are no financial, market or business or environmental factors, material or otherwise that may
affect you financially.

 

The
Bank reserves the right upon review (with (7) days prior notification to you) to cancel, suspend, restructure, vary or amend the
Facility and the operating account(s) for the Facility or any terms and conditions herein prior to any utilization or disbursement
of the Facility or any portion thereof.

 

 

 

 

M/B/SME Property & Business Financing-i/ LO
(02092014)

Page 23 of 44

Bio life Neutraceuticals Sdn. Bhd. {870055·M)

 

    	 

    	 

    

 

 

		14.	Right to Withdraw/ Cancel Facility Prior to
/ After Completion of Documentation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		15.	Representations and
Warranties

The
Bank has the right upon an event of default to do the following at any time whatsoever whether or not the Facility herein have
been disbursed or utilized:-

 

		a.	At any one time hereafter and notwithstanding
that the Security Documents has been completed, to withdraw or not make available the Facility or any part thereof upon the happening
of any event which in the Bank"s opinion would affect in any way your financial position and/or hinder the carrying on your
business affairs in accordance with sound financial, industrial or commercial standards and practices and/or would jeopardise the
Bank's security position and/or which is a default in respect of any of the requirements of the Bank whatsoever at any time and
from time to time and the decision of the Bank shall be final and conclusive. The Bank has the absolute discretion to decide on
the implementation of this condition (whenever deemed applicable).

 

		b.	Notwithstanding that the Security Documents
has been duly approved, accepted and/or completed, the Bank has the absolute right and discretion not to release or make available
the Facility or any part thereof or to withdraw, terminate and/or terminate the Facility and the operating account(s) for the Facility
therein granted to you immediately upon the Bank becoming aware that you and/or security party is/are or has/have been investigated
or is/are alleged to be involved and/or had committed any illegal activities or criminal offences of any nature whatsoever or will
be or have been allegedly subjected to any criminal prosecution and/or conviction and/or any security in respect of the Facility
held by the Bank is subjected to or at risk of freezing, seizure and forfeiture by the Federal Government and/or other relevant
authorities or regulatory bodies. In all events, the Bank's decision shall be final and conclusive.

 

		c.	Where applicable, to
withdraw this letter of offer in the event the terms and conditions of the Sale and Purchase Agreement (SPA) or such other document
required by the Bank are deemed to be unfavorable and not in the Bank's interest. In the event the SPA has not been given to the
Bank prior to issuance of this letter of offer, this Facility is subject to the Bank being satisfied with the terms of the SPA
upon it being forwarded to the Bank.

 

The
Bank has the right to suspend / freeze the operating account for the Facility granted by giving written notice.

 

		15.1	You acknowledge that the Bank has entered
into this letter of offer, in full reliance on your representations in the following terms:-

 

		(a)	Powers and authorisation: you have the powers
and legal authority to execute and deliver, and perform your obligations under this letter of offer and/or the Security Documents
which constitutes your valid and binding obligations enforceable in accordance with its terms and has not been terminated;

 

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page
24 of 44 Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

 

 

    	 

    	 

    

 

 

 

		(b)	Non-violation: neither the execution and
delivery of this letter of offer and/or the Security Documents nor the performance of any of the transactions contemplated in such
documents will contravene or constitute a default under any provision contained in any agreement, instrument, law, judgement, order,
license, permit or consent by which you or any of your/its assets is bound or affected;

 

		(c)	Consents: no authorisation, approval, consent,
licence, exemption, registration, recording, filing or notarisation and no payment of any duty or tax and no other action whatsoever
which has not been duly and unconditionally obtained, made or taken is necessary or desirable to ensure the validity, enforceability
or priority of your liabilities and obligations and the rights of the Bank under the Security Documents;

 

		(d)	No default: no event has occurred which constitutes,
or which with the giving of notice and/or the lapse of time and/or a relevant determination would constitute, a contravention of,
or default under, any agreement or instrument by which you or any of your assets is bound or affected;

 

		(e)	Litigation: no litigation, arbitration or
administrative proceeding or claim which would by itself or together with any other such proceedings or claims have been made against
you or the Security Party or against your or the Security Party's assets;

 

		(f)	Change in Customer: Since the date you applied
for the Facility there has been no material alterations or changes which could or might adversely affect your ability to perform
your obligations under the Security Documents;

 

		(g)	Information: the information furnished or
to be furnished by you in connection with the Facility does not contain any untrue statement or omit to state any fact the omission
of which makes the statements therein, in the light of the circumstances under which they were made are misleading in any material
respect and there is no material omission in respect thereof, and all expressions of expectation, intention, belief and opinion
contained therein were honestly made on reasonable grounds after due and careful enquiry by you;

 

		(h)	Guidelines on Credit Transaction and Exposures
with Connected Parties for Islamic Banks : None of the Security Party or the spouses, parents, children of such Security Party
are directors, officers or in any way otherwise connected with the Bank within the meaning of the said Guidelines;

 

		(i)	Where you are a company, you are duly incorporated
and validly existing under the Companies Act, 1965 and the laws of Malaysia and has full power and authority to own assets, to
apply and accept the Facility and carry on your business as it is now being carried out;

 

		(j)	Event of Default: no event of default has
occurred and/or is continuing.

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 25 of 44
Bio Life Neutraceuticals Sdn. Bhd. (870055·M)

    	 

    	 

    

 

 

 

		15.2	Survival

 

The
representations and warranties set out herein shall survive the signing and delivery of this letter of offer and any utilisation
of the Facility and until the full and final settlement of the Facility, as the case may be.

 

		16.	Covenants

		16.1	Affirmative Covenants

 

By
your acceptance of the Facility, you undertake that so long as the Facility or any part thereof or any profit or any other sum
from time to time payable hereunder shall remain outstanding you shall:-

 

		(a)	at all times operate your account actively
and satisfactorily and observe the approved limit of the Facility;

 

		(b)	keep the Bank in close touch with the progress
of your business and furnish the Bank with such information to such extent and in such form and detail as the Bank may from time
to time reasonably require;

 

		(c)	carry on and conduct your affairs and businesses
with all due diligence and efficiency and in accordance with sound financial and business standards and practices;

 

		(d)	keep full and particular accounts of the
carrying on of your business or businesses and cause the same to be properly posted up to date and furnish the Bank with audited
annual financial statements within six (6) months or such other period determined by the Bank of the close of each financial year;

 

		(e)	notify the Bank of the occurrence of any
Event of Default or of any material adverse change in your condition (financial or otherwise) or of any other occurrence of which
you become aware which in the Bank's reasonable opinion might adversely affect your ability fully to perform its obligations under
this letter of offer;

 

		(f)	notify the Bank should any of your authorised
signatories be no longer authorised to sign or otherwise to act on your behalf hereunder.

 

		(g)	appoint from time to time such auditor or
firm of auditors acceptable to the Bank and authorise such auditor or firm of auditors to supply the Bank with a certified copy
of any communication sent by such auditor to you and further to communicate directly with the Bank at any time in respect of any
matter connected with your accounts and operations subordinate all your existing and future shareholders and/or directors and /or
related companies advances to the Bank.

 

		(h)	notify the Bank in the event of any change
in your residential status.

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 26 of 44
Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

    	 

    	 

    

 

 

 

		(i)	immediately notify the Bank in the event
of change of nature of your business (if applicable). In the event such change results in a breach to the Shariah principles, the
Bank reserves the right to terminate the Facility whereupon the indebtedness shall be payable on demand.

 

		16.2	Negative Covenants

 

You further undertake
by its acceptance of the Facility you will not without the Bank's prior written consent:·

 

		(a)	incur assume guarantee or permit to exist
any indebtedness except for the indebtedness under this letter of offer and any indebtedness which has been disclosed by you to
the Bank prior to the date of this letter of offer.

 

		(b)	create or permit to exist any lien on any
of your assets except any tax or other statutory lien provided that such lien shall be discharged within thirty (30) days after
final adjudication, "lien" being defined to include any assignment mortgage pledge charge privilege encumbrance and/or
priority of any kind and "assets" being defined to include any right interest receivable revenue and/or property movable
or immovable of any kind, present or future;

 

		(c)	enter into any transaction with any person
except in the ordinary course of business on ordinary commercial terms and on the basis of arm's length arrangements or establish
any exclusive purchasing or sales agency or enter into any transaction whereby you may pay more than the ordinary commercial price
for any purchase or may receive less than the full ex-work commercial price (subject to normal trade discounts) for its products;

 

		(d)	enter into any partnership profit-sharing
or royalty agreement or other similar arrangement whereby your income or profits are or might be shared with any person firm or
company or enter into any management contract or similar arrangement whereby your business or operations are managed by any other
person firm or company;

 

		(e)	make or have any subsidiary make or permit
to give financing or lending or make advances to your holding company or any related corporation or to others including a director
of any subsidiary or holding or any related corporation or make investments in other companies or enterprise or guarantee any person
including a director of any subsidiary or holding or any related corporation enterprise or company (other than normal trade credit
or trade guarantees or temporary financings to staff customers contractors or suppliers in the ordinary course of business) PROVIDED
that you shall be at liberty to invest in short term marketable securities acquired solely so as to utilize such funds as are not
immediately required for its business;

 

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 27 of 44 Bio
Ufe Neutraceuticals Sdn. Bhd. {870055-M)

 

    	 

    	 

    

 

 

 

		(f)	add to, delete, vary or amend your Memorandum
and Articles of Association in any manner which would be inconsistent with the provisions of this letter of offer or the nature
of your business, or sell, transfer, lease or otherwise dispose of all or a substantial part of your capital assets, or undertake
or permit any merger, consolidation or reorganization if the result in so doing will materially and adversely affect your financial
condition;

 

		(g)	save in the normal course of business, dispose of any your assets

or investments;

 

		(h)	allow any court judgment entered against
you to be unsatisfied for more than fourteen (14) days;

 

		(i)	decrease or in any way alter your authorized
or issued capital, whether by varying the amount structure or value thereof or the rights attached thereto or connected to any
of its share capital into stock or by consolidating, dividing or subdividing all or any of its shares.

 

		(j)	declare or pay dividends to your shareholders
if there are monies under this Facility due and payable;

 

		(k)	undertake or permit any merger, consolidation or reorganization;

 

		(l)	make any prepayment of any advances or financing
by your shareholders, directors or related companies.

 

		17.	Debit to
Account

 

 

 

 

		18.	Evidence of

Indebtedness

 

 

 

		19.	Events of

Default

Any
monies due and payable to the Bank, or advanced by the Bank on your behalf may be debited to any account as the Bank deems fit
and if debited to your current account, may be treated as an advance on an overdraft facility. Notification of at least twenty
one (21) days will be given to you prior to the effective date of the implementation.

 

In
any legal action or proceedings relating to the Facility, a certificate of the Bank as to any amount due to it under the Facility
shall, in the absence of manifest error, be conclusive evidence that such amount is in fact due and payable.

 

Notwithstanding
any other provision herein relating to any payment of Facility, the Facility or any part thereof may be terminated whereupon all
indebtedness being outstanding and unpaid thereon and all other moneys owing to the Bank shall be payable on demand in the event:-

 

		(a)	You and/or Security Party (i) defaults or
fails to pay any amount due in respect of the Facility, or (ii) fails to pay on due date any monies payable by you, and/or Security
Party under any agreement or arrangement to any other financier;

 

		(b)	You and/or Security Party dies, become insane
or is adjudicated a bankrupt or is wound up;

 

		(c)	You and/or Security Party fails to observe
or perform any of the agreements, covenants, stipulations, terms and conditions under herein to be observed or performed;

 

MIB/SME Property
& Business Financing-i/ LO (02092014)

 

Page 28 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

 

		(d)	A distress or execution is levied or enforced
upon any of your property or assets and/or Security Party's property or assets and is not satisfied within seven (7) days from
the date of commencement of such distress or execution;

 

		(e)	Legal proceedings, suit or action of any
kind is instituted against you and/or Security Party;

 

		(f)	You and/or Security Party are unable to
pay any debt or suspend payment thereof or enter into any arrangement or composition with your creditors or your guarantor or security
party's creditor, or commit an act of bankruptcy;

 

		(g)	Any event occurs or circumstances arose including
changes in the financial condition which in the opinion of the Bank would materially affect your ability and/or Security Party's
ability to perform or comply with your/its obligations to the Bank;

 

		(h)	The Bank is in the opinion that the security
in favour of the Bank is in jeopardy;

 

		(i)	You have been listed as bad cheque offender
by the Biro Maklumat cek/Dishonoured Cheque Information System set up by Bank Negara Malaysia;

 

		(j)	Any part of your and/or the Security Party
or your or their subsidiaries assets shall be acquired, seized or otherwise appropriated or nationalized by any person acting or
purporting to act under the authority of the government, or you shall have been prevented from exercising your normal control and
possession over such asset;

 

		(k)	You enter into or propose to enter into or
a declaration is made by any competent court or authority, a moratorium on the payment of indebtedness or other suspension of payments
generally;

 

		(l)	Such other events of defaults as may be
advised by the Bank's solicitors.

 

then,
at once or at any time thereafter, the Bank may, by notice to you declare the Facility to be immediately due and payable whereupon:

		(i)	the indebtedness shall become immediately due; and

		(ii)	no further utilization of the Facility shall
be made and the Facility shall be cancelled.

 

		20.	Set OffThe Bank may after a seven (7)
days notice given to you, combine, consolidate or merge all or any of your accounts with, and liabilities the Bank and may set
off or transfer any sum outstanding to the credit of any such accounts in or towards the satisfaction of any of your liabilities
to the Bank under the Facility.

 

 

 

 

MIB/SME Property & Business Financing·i/
LO (02092014)

Page 29 of 44

Bio life Neutraceuticals Sdn. Bhd. (870055·M)

 

 

    	 

    	 

    

 

 

The Bank may concurrently
earmark the available funds in your accounts against the outstanding balance of the facility(s) upon the issuance of the notice
to you.

 

		21.	Cross Default

 

 

 

 

 

		22.	Indemnity

 

 

 

 

 

		23.	Increased

Costs/Capital
Adequacy

If
any of your indebtedness becomes due and is capable of being declared due before its maturity or when called, then and in such
event the Facility together with all monies payable under such accounts or any other banking facility shall immediately become
due and payable.

 

You
shall fully indemnify the Bank against any loss or expenses (including legal fees on a solicitors and client basis) which the Bank
may incur as a consequence of any default on your part in due performance of any of the obligations expressed to be assumed by
you in relation to the Facility.

 

Where
the Bank determines that the introduction or change in any law (or any change in the interpretation or application of any law),
regulation, directive or request from any governmental or regulatory authority (whether or not having the force of law) imposes
or modifies any capital adequacy or similar requirement (including, without limitation, a requirement, which affects the Bank's
allocation of capital resources to its obligations) and, as a result, increases the cost to the Bank of making or maintaining or
of funding any amount paid out or contingently to be paid out under the Facility or obliges the Bank to make any payment or calculated
by reference the amount of any sum received or receivable by the Bank, then:-

 

		a.	the Bank shall notify you of such event upon
its becoming aware of the same;

 

		b.	the Bank shall be entitled to vary the Effective
Profit Rate on the Facility;

 

		c.	you shall promptly pay to the Bank on demand
such amount as the Bank from time to time and at any time certify to be necessary to compensate the Bank for such additional cost
or liability; and

 

		d.	at any time thereafter, so long as the circumstances
giving rise to the obligation to make the compensating payment continue:·

 

		i.	at your election by notice to the Bank, the
Bank's obligation to fund any further utilization shall terminate and the Facility shall be cancelled to such extent; and

 

		ii.	you may (on giving not less than 30 days
notice) (which shall be irrevocable), prepay the Facility together with accrued profit thereon to the date of prepayment and other
indebtedness and upon receipt by the Bank of notice of such election, the Facility shall be cancelled.

 

 

 

 

 

 

MIBISME Property& Business Financing-i/ LO
(02092014)

Page 30 of 44

Bio life Neutraceuticals Sdn. Bhd. (870055-M)

 

 

    	 

    	 

    

 

 

		24.	Illegality

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		25.	Statement by

Bank

 

 

		26.	Guarantee

 

 

 

 

 

		27.	Change In

Shareholding

 

 

 

 

		28.	Changes in

Circumstances

 

 

 

 

		29.	Notices

Where
the Bank determines that the introduction, imposition or variation of any law, order, rule, regulation or official directive (whether
or not having the force of law) or any change in the interpretation or application thereof or any compliance therewith makes it
apparent to the Bank that it will be unlawful or impractical without breaching any such law, order, regulation or official directive
(whether or not having the force of law) for the Bank to maintain, fund or give effect to its obligations herein:·

 

		a.	the Bank's obligations to fund any further
utilization shall terminate and the Facility shall be cancelled to such extent; and

 

		b.	if any utilization has been made, you shall
prepay the Facility without premium or penalty to the Bank as the Bank shall direct and certify to be necessary to comply with
the relevant law.

 

A
statement by a duly authorized officer of the Bank for the time being, as to any amount due and payable shall, saves for manifest
error be conclusive evidence for all purposes.

 

Notwithstanding
anything herein contained the fact that one or more of the abovenamed guarantors may not have executed a guarantee in form and
substance acceptable to the Bank, the guarantee when executed shall be binding and enforceable against each guarantor who executes
the same.

 

You
shall not without first obtaining the prior written consent of the Bank, allow any change in its existing shareholders or their
respective shareholdings, failing, which the Bank may declare the banking facilities to be cancelled and all indebtedness to be
immediately due and payable.

 

The obligation of the
Bank to continue to make available to you the Facility shall, in addition to the terms and conditions herein and there being no
default by you, be subject to there being no change in circumstances which may affect the ability of the Bank to grant the Facility
or which may increase the cost to the Bank of doing so.

 

		a.	Any notice or communication may be in writing
and may be delivered personally, by post, telex, cable or facsimile to you at the address herein stated. Proof of posting or dispatch
of any notice or communication to you shall be deemed to be proof of receipt:-

 

		i.	if personally delivered, at the time of delivery; or

		ii.	if posted, on the second business day after posting; or

		iii.	in the case of telex or cable, on the business
day immediately after transmission; or

		iv.	in the case of a facsimile, on the business
day immediately after transmission provided that the Bank has received an answer back confirmation.

 

		b.	No change in your address herein stated
howsoever brought about shall be effective or binding on the Bank unless actual notice of .the change of address has been given
to the Bank.

 

 

 

M/B/SME Property & Business Financing·i/
LO (02092014)

 

Page 31 of 44
Bio life Neutraceuticals Sdn. Bhd. (870055-M}

 

 

    	 

    	 

    

 

 

		30.	Service of Legal Process

 

 

 

 

 

 

 

		31.	Severability

 

 

 

 

 

 

 

 

		32.	Waiver

 

 

 

 

 

 

 

		33.	DCHEQS

 

 

 

 

 

		34.	Guidelines on Credit Transactions and Exposures with Connected Parties
for Islamic Banks by Bank Negara Malaysia (BNM)

 

 

 

 

		35.	Time

 

		36.	Successors Bound

 

		37.	Assignment

 

		a.	The service of any legal
process may be given by prepaid registered or ordinary post sent to you at the address herein stated and such legal process shall
be deemed to have been duly served after the expiration of five (5) days from the date it is posted.

 

		b.	No change in your address herein stated howsoever
brought about shall be effective or binding on the Bank unless actual notice of the change of address has been given to the Bank.

 

Any
term, condition, stipulation, provision, covenant or undertaking contained herein which is illegal, prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such illegality, prohibition or unenforceability
without invalidating the remaining provisions hereof and any such illegality, prohibition or unenforceability in any jurisdiction
shall not invalidate or render illegal, void or unenforceable any such term, condition, stipulation, provision, covenant or undertaking
in any other jurisdiction.

 

No
delay by the Bank in exercising nor any omission to exercise any right, power or remedy accruing to the Bank upon any default shall
affect, impair or prejudice any right, power or remedy or be construed to be a waiver thereof or any acquiescence in such default,
nor shall any action by the Bank in respect of any default, impair or prejudice any right, power or remedy of the Bank in respect
of any subsequent default.

 

In
accordance with the prevailing Dishonoured Cheque Information System (DCHEQS) guidelines issued by Bank Negara Malaysia from time
to time, the Bank reserves the right with notice given to you at least twenty one (21) days to close your current account(s) whether
held solely or jointly with others to comply with the guidelines.

 

In
accordance with the Guidelines on Credit Transaction and Exposures with Connected Parties for Islamic Banks and/or of any replacement
guidelines/specifications/circulars issued pursuant to the Islamic Financial Services Act 2013, the approval and the operation
or utilization of such facility is strictly conditional that neither you or your partners or directors, shareholders, managers
or agents of your firm or company or Security Party for the Facility is directly related to any director, officer or employee of
the Bank currently or at any time in the future either as a parent, spouse or child. The Bank reserves the right to terminate the
Facility and you hereby undertake to advise the Bank immediately if the above relationship is established or discovered at any
time.

 

Time shall be the essence of this
letter of offer.

 

This
letter of offer shall be binding upon your successors in title and on the successors in title and assigns of the Bank.

 

The
Bank may at any time without requiring your consent or concurrence assigns or transfers its rights, interest and obligations hereunder.
You shall not assign or transfer your rights hereunder or any interest herein. All costs and expenses incidental to such assignment
or transfer, shall be payable by you.

 

 

MIB/SME Property & Business Financing-i/ LO (02092014)

Page 32 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M}

    	 

    	 

    

 

 

 

		38.	Valuation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		39.	Takaful /

insurance

 

You
hereby authorize the Bank to value the property charged or assigned to the Bank as security for the facility(s) annually or at
such interval as the Bank shall in its discretion decide by any valuer or any officer of the Bank or any person of the Bank's choice
from either the Bank's panel valuer or such other valuer of your choice as the Bank may require (for non-panel valuer, subject
to the approval of the Bank) at your sole cost and expense and in the event such valuation reveals that the forced sale value of
the property is lower than that at the date hereof the Bank shall have the absolute discretion to require to you within fourteen
(14) days from the date of the notice from the Bank to charge, pledge, mortgage or deposit with the Bank your stock's and share,
assets movable property and/or the issue document of title, if any, or all immovable properties vested in you of such value as
the Bank may from time to time require or the payment of the total amount owing for the time being under the facility(s).

 

In
the event the final valuation differs from the preliminary estimate at the point of processing / approving the facility(s) inter
alia due to fraud of the valuation report or any other reasons that will affect the value of the property, the Bank is entitled
to terminate or cancel or reduce the amount of the facility(s) notwithstanding the security documentation have been completed.

 

		a)	All assets/properties charged/assigned to the Bank as security shall be
adequately covered/insured by takaful/insurance against all risks including but not limited against loss or damage through fire,
earthquake, lighting, riot, strike or, malicious damage for their full value or replacement costs whichever is higher or as the
Bank may require and shall be taken from the Bank's approved takaful operator/insurance company. In addition, to ensure the Bank
to be stated as mortgagee/chargee in the takaful/insurance certificate and such takaful/insurance shall not be terminated without
the Bank's prior written consent.

 

		b)	Fire takaful/insurance under Buildings In
the Course of Construction (BICC) or Contractors All Risk is to be taken by you for financing of properties under construction
(where applicable).

 

		c)	Fire takaful/insurance is to be taken on
your company's fixed and floating assets where the bank has taken a debenture on your company's assets (where applicable).

 

		d)	All takaful plans/insurance policies will
be taken up at your own costs and expenses and the Bank reserves the right to pay the contribution/premium for any takaful plan/insurance
policy on your behalf and to debit your account with notice accordingly.

 

		e)	The Bank will from time to time review the
adequacy of the takaful/insurance coverage in ensuring that the property is sufficiently insured. The excess contribution/premium,
if any, shall be advised accordingly in the yearly renewal notice.

 

 

 

 

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 33 of 44

Bio
Life Neutraceuticals
Sdn. Bhd. {870055-M)

 

    	 

    	 

    

 

 

 

		40.	Utilisation of Facility

 

 

 

 

 

 

 

		41.	Governing Law

 

 

 

 

		42.	Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		43.	Foreign Account Tax Compliance Act ("FATCA")

 

Any
request for utilisation of any facility shall be in writing, given in accordance with the requirements as to form, timing and accompanying
documents as may be specified by the Bank generally in accordance with the Bank's standard terms and conditions applicable to the
relevant facility and subject to the Bank being satisfied (and in this respect the Bank's decision shall be conclusive) that there
are no material changes affecting your financial condition after acceptance of the facility(s).

 

You
agree that this letter of offer and all the documents executed or to be executed in connection herewith shall be governed by the
Laws of Malaysia and you further agree to submit to the jurisdiction of the respective Courts of Malaysia.

 

		(i)	Any goods and services tax or levies now
or hereafter imposed by law or required to be paid in respect of any monies payable to or to be received by the Bank on any expenses
incurred or to be incurred by the Bank (except where prohibited by law) shall be borne by you.

 

		(ii)	All other taxes, duties or government charges
now or hereafter imposed or levied in connection with this Facility shall be borne by you.

 

		(iii)	You hereby agree that the Bank reserves the right to debit any of your
banking account(s) for such taxes or levies payable by you. In the event, such debiting causes your banking account(s) to be overdrawn
and not regularised within the specific period determined by the Bank, late payment charges shall be imposed on the excess thereto.

 

You hereby consent that the Bank may:-

 

		(a)	report your information to the relevant
regulatory authorities in accordance with the requirements of the FATCA as may be stipulated by laws, regulations, agreements or
regulatory guidelines or directives;

 

		(b)	withhold from your account(s) such amounts
in accordance with the requirements of FATCA as may be stipulated by applicable laws, regulations, agreement, or regulatory guidelines
or directives; and

 

		(c)	classify you as a recalcitrant account holder
or non-participating foreign financial institution ("NFFI") and/or
suspend or terminate the account(s) granted to you, in the event that you fail to provide accurate and/or complete information
and/or documentation as the Bank may require.

 

In
addition to the above, you hereby undertake to provide the Bank with written notice within thirty (30) calendar days, should there
be any change in information provided to the Bank.

 

 

 

 

MIB/SME Property & Business Financing·i/
LO (02092014)

Page 34 of 44
Bio Life Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

 

		44.	Privity to

Agreement

 

 

 

 

 

 

 

 

 

		45.	Strategic Trade Act 2010 (If
applicable)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		46.	Anti-Money

Laundering and Anti-Terrorism
Financing Act 2001

You
hereby acknowledge, agree and confirm that regardless of anything contained in any agreement/ contract including but not limited
to a sale and purchase agreement for purchase of movable or immovable asset entered between you and the vendor or any third party
where the Bank has no privity to the said agreement/contract and is under no obligation whatsoever to perform any term or condition
of the said agreement/contract irrespective of whether or not the Bank has been notified of such term or condition, and the Bank
shall not be liable in any manner whatsoever to you or any other party for the Bank's refusal or failure to perform such term or
condition.

 

You
hereby agree covenant and undertake that the facility(s) herein shall not be utilised for transactions involving goods, items and
services identified and/or classified as strategic items for the purposes of the Strategic Trade Act 2010 including the importation,
exportation, transhipment, brokering, marketing, distribution or all other transactions not specifically stated herein involving
such strategic items and/or in any way act in contravention of the Strategic Trade Act 201O
and you further agree and covenant that the Bank may at its absolute discretion and without assigning any reasons thereto
decline to disburse the facility(s), allow further drawdowns, make payments or process the payment of the facility(s) herein or
accept and negotiate any trade facilities granted to you or requested to be negotiated by you if such transaction relate to the
said strategic items and the Bank further reserves its absolute right to declare an event of default and recall or cancel the facility(s)
granted herein as a result of such transactions. You shall absolve the Bank from any liability arising from such transactions and
shall further indemnify and keep the Bank indemnified on a full indemnity basis against any fines and/or penalties imposed on the
Bank and against any penal sanctions imposed on the Bank or of the Bank as a result of any act or conduct or contravention by you
of the Strategic Trade Act 2010 and/or causing the Bank to in any way contravene the Strategic Trade Act 2010.

 

During the tenure of the facility(s), you undertake
that you shall not:-

 

		i.	Engage, directly or indirectly, in a transaction
that involves proceeds of any unlawful activity;

 

		ii.	Acquire, receive, possess, disguise, transfer,
convert, exchange, carry, dispose, use, remove from or bring into Malaysia proceeds of any
unlawful activity; or

 

		iii.	Conceal, disguise or impede the establishment
of the true nature, origin, location, movement, disposition, title of, rights with respect to, or ownership of, proceeds of any
unlawful activity.

 

 

 

 

 

 

 

 

 

 

M/B/SME Property & Business Financing·I/
LO (02092014)

Page 35 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

		47.	Disclosure of

Customer Information and Personal Data
under the Islamic Financial Services Act 2013 ("IFSA")

and the Personal Data Protection
Act 2010 ("PDPA")

 

		A.	If you are a company or incorporated entity,
you hereby warrant and represent to the Bank that:·

 

		i.	You give your consent
to the Bank to disclose information and/or documents supplied in connection or pertaining to the facility(s), your business and
your banking account(s) with the Bank (including future accounts) to associate company or parent company of the Bank or Bank's
subsidiaries or any company which are or in the future may be a related company to the Bank, agent, auditors, legal counsels, professional
advisors or representatives, the Credit Bureau or any other banking or regulatory authorities, any co-debtor, joint account holder,
guarantor, chargor or surety, security party, party making a claim under any third party payment instrument or trade document,
any other person who has undertaken liability for the facility(s) with the Bank or pursuant to any law or legal process or in connection
with any action, suit or proceeding relating to the facility(s), any bank or financial institution in relation to the provision
of financing in connection with the Bank or the Bank's related companies' products or services or otherwise and any person to whom
disclosure is permitted or required by law, regulation or any governmental agency.

 

		ii.	You also give your consent to the Bank to
disclose any information pertaining to you and/or your account(s) to Etiqa Takaful Berhad/Etiqa Insurance Berhad ("Etiqa")
or other takaful operator or Insurance company (if required) in the event that any application for any takaful/insurance coverage
is submitted by you to Etiqa or other takaful operator/insurance company and such information and/or verification on such information
is required by Etiqa or other takaful operator /insurance company.

 

		iii.	You give your consent to the Bank to disclose
such information about you as it may have in its possession to Credit Guarantee Corporation Malaysia Berhad ("CGC") and/
or its agents as the Bank may deem necessary in its absolute discretion.

 

		iv.	You agree and acknowledge that the Bank may
request you from time to time to provide the personal data and information of you, your guarantor's and/or any third party security
providers' (including but not limited to) directors, shareholders, employees, representatives and/or any other individual ("the
Individual") in the course of your contract and/or transactions with the Bank ("Personal Data").

 

		v.	Maybank Group Privacy Notice which is posted
in our website www.maybank2u.com.my outlines how the Maybank Group collects, uses, maintains,
stores, discloses, secures and retains the Personal Data. You are to refer to the Maybank Group Privacy Notice and prior to providing
us with the Individual's Personal Data, you are to inform the Individual of the Maybank Group Privacy Notice. The Bank together
with its related/associated companies are collectively referred to as "Maybank Group".

 

MIB/SME Property
& Business Financing·i/ LO (02092014)

Page
36 of
44 Bio Life Neutraceuticals Sdn. Bhd. (870055·M)

 

    	 

    	 

    

 

 

 

vi.
You hereby warrant that you have complied with the requirements of POPA and have obtained the relevant consents from the Individual
in relation to the processing and disclosure of their Personal Data.

 

		B.	If you are an individual or unincorporated
entity, you hereby warrant and represent to the Bank that:-

 

		i.	Subject to your instruction restricting
disclosure (if any) for the purposes of marketing activities, you consent to and authorize the Bank to collect, process, disclose,
transfer your personal data to other entities within Maybank Group including its branches in Malaysia and in other countries as
well as is local and overseas subsidiaries and other external parties, including but not limited to the parties/bodies listed below
for the maintenance, storage and retention of your personal data, within or outside of Malaysia, in order to process your application
for products and services and subsequently to continue performing the contractual agreements entered between you and any entity
within Maybank Group.

 

		ii.	You consent and authorize the Bank to collect,
process, disclose, transfer, maintain, store and retain your personal data to other entities within the Maybank Group including
its branches in Malaysia and in other countries as well as local and overseas subsidiaries and other external authorised agents.

 

		iii.	You consent to the Bank conducting credit
checks and verification of information given by you in your application for the financing facility or services with any credit
bureaus or corporation set up for the purpose of collecting and providing credit or other information. You also consent to the
Bank's disclosure of your financial condition, details of accounts, account relationship with the Bank including credit balances
to:-

 

		a.	government or regulatory authorities in
Malaysia and elsewhere, including but not limited to Bank Negara Malaysia, Credit Bureau, Central Credit Reference Information
System ("CCRIS"), Cagamas Berhad, Credit Guarantee Corporation Malaysia Berhad and Syarikat Jaminan Kredit Perumahan
Berhad;

 

		b.	companies which are related to the Bank
by virtue of Section 6 of the Companies Act 1965, or any associated company of the Bank or of its parent company (the Bank together
with its related/associated companies are collectively referred to as "Maybank Group");

 

		c.	party(s) providing services (including outsourcing
vendors, lawyers, nominees, custodians, centralised securities depository
or registrar, debt collection agents) to the Bank;

 

		d.	the Bank's agents, consultants and professional advisers;

 

 

MIB/SME Property & Business Financing-i/
LO (02092014)

Page 37 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

		e.	the Bank's or any of the Maybank Group's assignees;

		f.	the police or any investigating officer
conducting any investigation; and

 

		g.	any person to whom disclosure is permitted
or required by any law, regulation, governmental directive or request.

 

		iv.	The Bank may, subject to compliance with
the applicable regulatory rules or guidelines, use or apply any information relating to you collected, compiled, or obtained by
the Bank through or by whatever means and methods for such purposes as determined by the Bank.

 

		v.	Subject to your express consent, you hereby
agree that the Bank's employees, representatives and/or agents to contact you from time to time through personal visits or oral
communication effected via any means of communication including but not limited to telephone calls regarding any products or services
promotion unless objected to in writing by you.

 

		vi.	You also declare that all personal information
and data set forth herein is/are all true, up to date and accurate and should there be any changes to any personal information
or data set forth herein, you shall notify the Bank immediately.

 

		vii.	You do hereby acknowledge that the Bank
may request you from time to time to provide the personal data and information of your personal guarantor's and/or any third party
security providers ("the Individual") in the course of your financing contract and/or transactions with the Bank ("Third
Party Personal Data").

 

		viii.	You hereby agree to draw the Individual's
attention to the Maybank Group Privacy Notice which is posted in our website www.maybank2u.com.myand which
outlines how the Maybank Group collects, uses, maintains, stores, discloses, secures and retains the Personal Data prior to providing
the Bank with the Individual's Personal Data.

 

		ix.	You hereby warrant that you have complied
with the requirements of PDPA and have obtained the relevant consents from the Individual in relation to the processing and disclosure
of their Personal Data.

 

[End of Annexure 2]

 

 

 

 

 

 

 

 

 

 

 

 

MIB/SME Property & Business Financing-i/ LO
(02092014)

Page 38 of 44

Bio life
Neutraceuticals Sdn. Bhd. (870055-M)

 

 

 

    	 

    	 

    

 

 

 

 

ATTACHMENT

 

Asset Sale Agreement

 

 

THIS AGREEMENT is made
the PARTIES:-

day of 21 Oct 2016

		(1)	MAYBANK ISLAMIC BERHAD (Company No. 787435-M)
a company incorporated in Malaysia and having its registered address at 14th
Floor, Menara Maybank, No. 100 Jalan Tun Perak, 50050 Kuala Lumpur and includes its successors
in title and assigns (hereinafter referred to as "Bank") of the one part; and

 

		(2)	The Party whose particulars are set out
in Section 2 of the Schedule hereto (hereinafter referred to as "Customer") of the other part.

 

RECITAL:-

 

Pursuant
to the Letter of Offer dated the day and year as stated in Section 1 of the Schedule hereto ("Letter of Offer") and in
accordance to the financing procedure of the Bank, the Customer has undertaken to purchase the commodity ("Commodity")
stated in Section 3 of the Schedule hereto upon the terms and conditions therein and herein contained.

 

IT IS HEREBY AGREED as follows:-

 

		1.	The Bank hereby sells to the Customer and
the Customer hereby purchases from the Bank the Commodity at a sale price as stated in Section 4
of the Schedule hereto ("Bank's Sale Price") and payable on deferred payment terms upon
the terms and conditions herein contained.

 

		2.	Upon execution of this Agreement, all rights
title and benefits to the Commodity shall pass to the Customer.

 

		3.	'fhe Bank's Sale Price and all other monies
covenanted to be paid under the Facility shall be paid in full within the tenure stated in Section 5 of the Schedule hereto ("Tenure")
at the time and in the manner as stated in Section 6 of the Schedule hereto.

 

		4.	The Customer is purchasing the Commodity
unconditionally and without reservation on an "as is where is" basis and shall have no remedy against the Bank in respect
of quality, condition, or otherwise in respect of the Commodity.

 

		5.	Each party acknowledges that the Commodity
shall be capable of physical delivery. The Customer may request the physical delivery of the Commodity provided that the Bank shall
have received such instruction from the Customer in the form of a fourteen days prior written notice to the Bank. All costs associated
with the physical delivery of the commodity, including the delivery costs, storage costs and takaful/insurance, shall be borne
by the Customer.

 

		6.	Unless otherwise stated, the reference, terms
and conditions as set out in the Letter of Offer are hereby repeated and shall be binding upon the parties hereto and their successor
in-title and assigns of the Bank and personal representatives, successor-in-title of the Customer.

 

 

 

MIB/SME Property &
Business Financing-i/ LO (02092014)

Page 39 of 44 Bio Life
Neutraceuticals Sdn. Bhd. (870055-M)

 

    	 

    	 

    

 

 

		7.	This Agreement shall be
subject to the Mast
er
Facility Agreement to be
executed between the Customer and
the Bank in
relation to the Letter of Offer upon the terms and
conditions therein contained.

 

		8.	It is hereby agreed
that this Agreement
is an instrument
employed in one transaction to
secure the payment of the
Facility together with all
indebtedness thereto
within the meaning
of Section 4
(3) of
the Stamp Act 1949
and for the purpose of the
said section, this Agreement
is deemed
to be the subsidiary
instrument. Pursuant to Para 6
of the General Exemptions of the First
Schedule of the Stamp Act 1949
wherein this Agreement is
an additional instrument
strictly required for the purpose of compliance with
the Shariah principles,
this Agreement is exempted
from stamp duty.

 

[End of clause
of the Asset Sale Agreement]

 

 

 

IN
WITNESS WHEREOF the parties hereto have hereunto set their
hands or seal the
day and year above stated.

 

 

SIGNED by

for
and on behalf MAYBANK ISLAMIC
BERHAD

(Company
No.: 787435-M) Name:

PF
No:Thim Lee
Chu

(981733)

 

 

 

 

 

 

*THE COMMON
SEAL of

the
Customer was hereunto affixed
in the presence of:

 

MAYBANK ISLAMIC
BERHAD

 

	
        /s/THIM LEE CHU

by its Authorised Signatory

 

 

 

 

 

Director

 

or

*SIGNED
by

 

for
and on behalf
of the Customer

Director/ Secretary

 

 

 

/s/CHONG KHOOI YOU

Bio
Life Neutraceuticals Sdn.
Bhd. (870055-M)

(
Formerly
known as CK Harvest
(M) Sdn
. Bhd. )

Lot
6,  Jalan
Ria 3,
Kawasan
Perindustrian
Ria,
Jalan
Semenylh,43000
Kajang, Selangor.

Tel/
Fax: 03•87406720

 

 

 

 

 

 

 

MIB/SME
Property
& Busin
ess Financing-i/
LO (0
20920
14)

Page
40 of 44 Bio
Life Neutraceuticals
Sdn. Bhd. (870055-M)

    	 

    	 

    

 

 

 

 

 

 

 

 

Schedule

(Schedule to the Asset Sale
Agreement)

 

	
         

        Section
	
         

        Item
	
         

        Particulars

	
         

        1
	
         

        Letter of Offer
	
         

        Date:
        10'h
        October, 2016

        Facility Type:Commodity
        Murabahah Term Financing-i

        (CMTF·i)

	
         

        2
	
         

        Customer
	
         

        NameBIO LIFE NEUTRACEUTICALS SDN. BHD.

         

        Company No.870055-M

         

        Registered OfficeTingkat 2

        No. 17
        & 19, Jalan Brunei Barat Pudu

        55100 Kuala Lumpur.

         

        Business Address:Lot
        6, Jalan Ria 3

        Taman Perindustrian
        Ria Batu 18, Off Jalan Semenyih 43000 Kajang

        Selangor.

	
         

        3
	
         

        The Commodity
	
         

        Shariah
        compliant commodities determined by the Bank as per the e-certificate or such other evidence of ownership maintained by the Bank
        for this Facility.

	
         

        4
	
         

        Bank's Sale Price
	
         

        RM6,926,058-44

	5	Tenure	As per the Letter of Offer
	6	Payment	As per the Letter of Offer

 

 

 

 

 

 

 

 

 

 

M/B/SME Property &Business
Financing-i/ LO (02092014)

Page
41 of 44 Bio Life Neutraceuticals Sdn. Bhd. (870055·M)

 

    	 

    	 

    

 

 

 

 

 

 

 

 

ATTACHMENT

 

 

Asset Sale Agreement

 

 

THIS AGREEMENT is made
the PARTIES:-

day of 21OCT 2016

		(1)	MAYBANK ISLAMIC BERHAD (Company No. 787435-M)
a company incorporated in Malaysia and having its registered address at 14th
Floor, Menara Maybank, No. 100 Jalan Tun Perak, 50050 Kuala Lumpur and includes its successors
in title and assigns (hereinafter referred to as "Bank") of the one part; and

 

		(2)	The Party whose particulars are set out
in Section 2 of the Schedule hereto (hereinafter referred to as "Customer") of the other part.

 

RECITAL:-

 

Pursuant
to the Letter of Offer dated the day and year as stated in Section 1 of the Schedule hereto ("Letter of Offer") and in
accordance to the financing procedure of the Bank, the Customer has undertaken to purchase the commodity ("Commodity")
stated in Section 3 of the Schedule hereto upon the terms and conditions therein and herein contained.

 

IT IS HEREBY AGREED as follows:-

 

		1.	The Bank hereby sells to the Customer and
the Customer hereby purchases from the Bank the Commodity at a sale price as stated in Section 4 of the Schedule hereto ("Bank's
Sale Price") and payable on deferred payment terms upon the terms and conditions herein contained.

 

		2.	Upon execution of this Agreement, all rights
title and benefits to the Commodity shall pass to the Customer.

 

		3.	The Bank's Sale Price and all other monies
covenanted to be paid under the Facility shall be paid in full within the tenure stated in Section 5 of the Schedule hereto ("Tenure")
at the time and in the manner as stated in Section 6 of the Schedule hereto,

 

		4.	The Customer is purchasing the Commodity
unconditionally and without reservation on an "as is where is" basis and shall have no remedy against the Bank in respect
of quality, condition, or otherwise in respect of the Commodity.

 

		5.	Each party acknowledges that the Commodity
shall be capable of physical delivery, The Customer may request the physical delivery of the Commodity provided that the Bank shall
have received such instruction from the Customer in the form of a fourteen days prior written notice to the Bank. All costs associated
with the physical delivery of the commodity, including the delivery costs, storage costs and takaful/insurance, shall be borne
by the Customer.

 

 

 

MIB/SME Property
& Business Financing·i/ LO (02092014)

Page 42 of 44 Bio
Life Neutraceuticals Sdn. Bhd. (870055·M)

 

    	 

    	 

    

 

 

 

		6.	Unless
otherwise stated, the
reference, terms and
conditions as set out
in the Letter of
Offer are hereby
repeated and shall
be binding upon the parties hereto and their
successor in-title and assigns
of the Bank
and personal
representatives,
successor-in-title
of the Customer.

 

		7.	This
Agreement
shall be subject
to the Master Facility
Agreement
to be executed between
the
Customer and the Bank in
relation to the Letter
of Offer upon the terms and
conditions
therein contained.

 

		8.	It is
hereby agreed that this Agreement is an
instrument
employed in one transaction
to secure th e payment
of the Facility together with all indebtedness
there to
within the
meaning of Section 4 (3)
of the Stamp Act
1949 and for
the purpose of
the said section,
this
Agreement is deemed to be
the subsidiary instrument.
Pursuant to
Para 6
of the General
Exemptions
of the First Schedule
of the Stamp Act 1949
wherein this Agreement
is an
additional instrument
strictly required
for the purpose of compliance
with the Shariah
principles, this Agreements
exempted from stamp duty .

 

[End of
clause of the
Asset Sale Agreement]

 

 

 

IN
WITNESS WHEREOF the par
ti es hereto have hereunto
set their hands or seal
the day and year above stated.

 

 

SIGNED by

for
and on behalf MAYBANK
ISLAMIC BERHAD

(Company
No.: 787435-M)

Name:
PF No:

 

MAYBANK ISLAMIC
BERHAD

 

	
        /s/ THIM LEE CHU

by its Authorised Signatory

Thim Lee
Chu

(981733)

 

 

 

 

 

 

 

 

*THE
COMMON SEAL
of

the
Customer was hereunto affixed
in the presence of:

 

 

 

Director
or

*SIGNED
by

 

for and on behalf
of the Customer

 

Director
/ Secretary

 

	
        /s/ CHONG KHOOI YOU

 

 

 

Bio
Life Neutraceuticals
Sdn.Bhd.
(870055-M)

(
Formerly
known as CK
Harvest
(M) Sdn.
Bhd. )

Lot
6, Jalan
 Ria
3, Kawasan
Perindustrian
Ria,

Jalan
Semenylh,
43000 Kajang,
Selangor.

Tel/
Fax: 03-8740
6720

 

 

MIB/
SM E Property
& Business
Financing-i /
LO (0
2092014)

Page
43 of 44 Bio Life
Neutraceuticals Sdn. Bhd.
(870055-M)

    	 

    	 

    

 

 

 

 

 

Schedule

(Schedule to the Asset
Sale Agreement)

 

	
         

        Section
	
         

        Item
	
         

        Particulars

	
         

        1
	
         

        Letter of Offer
	
         

        Date:10th
        October, 2016

        Facility Type:Cash
        Line-i (CL-i)

	
         

        2
	
         

        Customer
	
        Name:BIO
        LIFE NEUTRACEUTICALS SON. BHD.

         

        Company No.870055-M

         

        Registered OfficeTingkat 2

        No. 17 & 19, Jalan
        Brunei Barat Pudu

        55100 Kuala Lumpur.

         

        Business AddressLot
        6, Jalan Ria 3 Taman Perindustrian Ria

        Batu 18, Off Jalan
        Semenyih 43000 Kajang

        Selangor.

	
         

        3
	
         

        The Commodity
	
         

        Shariah
        compliant commodities determined by the Bank as per the e-certificate or such other evidence of ownership maintained by the Bank
        for this Facility.

	
         

        4
	
         

        Bank's Sale Price
	
         

        RM1,532,500-00

	
         

        5
	
         

        Tenure
	
         

        As per the Letter of Offer

	
         

        6
	
         

        Payment
	
         

        As per the Letter of Offer

 

 

 

 

 

 

 

 

 

 

MIB/SME Property &
Business Financing-i/ LO (02092014)

Page
44 of 44 Bio Life Neutraceuticais Sdn. Bhd. (870055-M)Exhibit (a)(5)(F)

 

 

 

BROOKFIELD PROPERTY PARTNERS ANNOUNCES FINAL RESULTS OF SUBSTANTIAL ISSUER BID

 

All dollar references are in U.S. dollars, unless noted otherwise.

 

BROOKFIELD NEWS, March 28, 2019 — Brookfield Property Partners L.P. (“BPY”) (NASDAQ: BPY; TSX: BPY.UN) announced today the final results of its substantial issuer bid (the “Offer”) to purchase for cancellation up to $405 million of its limited partnership units (the “BPY Units”), which expired at 5:00 pm (Eastern Time) on March 25, 2019.

 

The Offer was open to holders of BPY Units (“BPY Unitholders”), holders of exchangeable limited partnership units of Brookfield Office Properties Exchange LP (“Exchange LP Unitholders”, and together with BPY Unitholders, the “Unitholders”) on an as exchanged basis (as exchanged, and together with the BPY Units, the “Units”) and holders of securities that are exchangeable into BPY Units prior to or at the time of the Offer.

 

In accordance with the terms and conditions of the Offer and based on a final count by AST Trust Company (Canada) (the “Depositary”), BPY has taken up and purchased for cancellation 13,981,839 Units at a purchase price of $21.00 per Unit (the “Purchase Price”), for an aggregate cost of approximately $294 million, excluding fees and expenses relating to the Offer.

 

The Offer was made by way of a “modified Dutch auction” with Offer prices ranging from $19.00 to $21.00 per Unit. Based on final results, 13,981,839 Units were properly tendered under the Offer and not withdrawn.

 

Payment for the purchased Units will be effected by the Depositary in accordance with the Offer and applicable law. Any Units tendered and not purchased will be returned to Unitholders promptly by the Depositary.

 

Under its separate substantial issuer bid, Brookfield Property REIT Inc., a subsidiary of BPY, has taken up 4,679,802 of its Class A shares at a purchase price of $20.30 per share, for an aggregate cost of approximately $95 million.

 

The Units expected to be purchased under these offers in aggregate represent approximately 1.8% of the Units issued and outstanding as of March 22, 2019 on a fully exchanged basis. After giving effect to these offers, 1,031,362,319 Units are expected to be issued and outstanding on a fully exchanged basis.

 

This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Units.

 

***

 

Brookfield Property Partners, through Brookfield Property Partners L.P. and its subsidiary Brookfield Property REIT Inc., is one of the world’s premier commercial real estate companies, with approximately $87 billion in total assets. We are leading owners, operators and investors in commercial real estate, with a diversified portfolio of premier office and retail assets, as well as interests in multifamily, triple net lease, logistics, hospitality, self-storage, student housing and

 

1

 

manufactured housing assets. Brookfield Property Partners L.P. is listed on the Nasdaq Stock Market and the Toronto Stock Exchange. Brookfield Property REIT Inc. is listed on the Nasdaq Stock Market. Further information is available at bpy.brookfield.com.

 

Brookfield Property Partners is the flagship listed real estate company of Brookfield Asset Management Inc., a leading global alternative asset manager with over $350 billion in assets under management.

 

Certain of our investor relations content is also available on our investor relations app. To download Brookfield Property Partners’ investor relations app, which offers access to SEC filings, press releases, presentations and more, please click here to download on your iPhone or iPad. To download the app on your Android mobile device, please click here.

 

Contact:

Matthew Cherry

Senior Vice President, Investor Relations & Communications

Tel: 212-417-7488

Email: matthew.cherry@brookfield.com

 

Forward-Looking Statements

 

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws and regulations. Forward-looking statements include statements that are predictive in nature or depend upon or refer to future events or conditions, include statements regarding our operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies and outlook, as well as the outlook for North American and international economies for the current fiscal year and subsequent periods, and include words such as “expects,” “anticipates,” “plans,” “believes,” “estimates,” “seeks,” “intends,” “targets,” “projects,” “forecasts,” “likely,” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.”

 

Although we believe that our anticipated future results, performance or achievements expressed or implied by the forward-looking statements and information are based upon reasonable assumptions and expectations, the reader should not place undue reliance on forward-looking statements and information because they involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, which may cause our actual results, performance or achievements to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking statements and information.

 

Factors that could cause actual results to differ materially from those contemplated or implied by forward-looking statements include, but are not limited to: risks incidental to the ownership and operation of real estate properties including local real estate conditions; the impact or unanticipated impact of general economic, political and market factors in the countries in which we do business; the ability to enter into new leases or renew leases on favorable terms; business competition; dependence on tenants’ financial condition; the use of debt to finance our business; the behavior of financial markets, including fluctuations in interest and foreign exchange rates; uncertainties of real estate development or redevelopment; global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; risks relating to our insurance coverage; the possible impact of international conflicts and other developments including terrorist acts; potential environmental liabilities; changes in tax laws and other tax related risks; dependence on management personnel; illiquidity of investments; the ability to complete and effectively integrate other acquisitions into existing operations and the ability to attain expected benefits therefrom; operational and reputational risks; catastrophic events, such as earthquakes and hurricanes; and other risks and factors detailed from time to time in our documents filed with the securities regulators in Canada and the United States.

 

We caution that the foregoing list of important factors that may affect future results is not exhaustive. When relying on our forward-looking statements or information, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements or information, whether written or oral, that may be as a result of new information, future events or otherwise.

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]